Propanc Biopharma, Inc. PPCB
1.71 USD -0.09 (-5.00%)
At closeNov 3, 2026, 4:10 PM EST
1.70 -0.01 -0.58%
After hours · Nov 3, 4:10 PM ET
1.69 Day range 1.76
1.69 52-week range 315.00
- YTD
- -98.73%
- 1 year
- -99.39%
- Market cap
- 1.77M
- EPS (ttm)
- -176.20
- YTD return
- -98.73%
- 1-year return
- -99.39%
- Volume
- 29.59K
- Avg volume
- 189.34K
- Open
- 1.75
- Previous close
- 1.80
- Day's range
- 1.69 – 1.76
- 52-week range
- 1.69 – 315.00
- Earnings date
- Sep 27, 2023
5D -0.71 (-29.46%)
Next earnings
Sep 27, 2023
Expected Sep 27, 2023. Consensus EPS estimate 0.00.
Financials — quick view
PPCB Revenue — quarterly 0
PPCB Net income — quarterly -4.57M
PPCB EPS — quarterly 62.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | 0.00 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.01 | — | — |
| Feb 20, 2024 | Dec 1, 2023 | 0.00 | -0.03 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.04 | — | — |
| Sep 27, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | 0.00 | — | — |
News
Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer 
Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients 
Propanc Biopharma Continues Clinical Development Program For Propanc Proenzyme; Targets February 2027 For Its First Clinical Site Initiation 
Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients - Propanc Biopharma Announces New Preclinical Data Supporting Potential Of PRP To Treat Chemotherapy Resistance In Pancreatic Cancer; PRP Monotherapy Reduced Cancer Cell Proliferation By ~50–54% And Suppressed Long-term Clonogenic Survival By Up To 59%
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability 
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans 
Propanc Biopharma Announces 1-For-10 Reverse Stock Split, Effective Oct. 26 
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans 
Propanc Biopharma Announces It Has Identified Pancreatic Proenzyme Formulation As Potential Strategy For Addressing Chemotherapy Resistance In Pancreatic Cancer
Your note
Sign in to keep a note on PPCB — it syncs with the Stock Master app.